Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIC: MEDI4736 (durvalumab) in previously treated advanced NSCLC
jRCT2080222742Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222742.